Phase II trial with oral idarubicin in advanced breast cancer

Massimo Lopez, Luigi Di Lauro, Paola Papaldo, Bonaventura Lazzaro, Fabrizio Ganzina, Nicola Di Pietro

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 % of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalInvestigational New Drugs
Volume4
Issue number1
DOIs
Publication statusPublished - Mar 1986

Fingerprint

Idarubicin
Breast Neoplasms
Leukopenia
Daunorubicin
Poisons
Anthracyclines
Alopecia
Thrombocytopenia
Nausea
Vomiting
Diarrhea
Pharmaceutical Preparations

Keywords

  • breast cancer
  • chemotherapy
  • idarubicin

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Lopez, M., Di Lauro, L., Papaldo, P., Lazzaro, B., Ganzina, F., & Di Pietro, N. (1986). Phase II trial with oral idarubicin in advanced breast cancer. Investigational New Drugs, 4(1), 39-42. https://doi.org/10.1007/BF00172014

Phase II trial with oral idarubicin in advanced breast cancer. / Lopez, Massimo; Di Lauro, Luigi; Papaldo, Paola; Lazzaro, Bonaventura; Ganzina, Fabrizio; Di Pietro, Nicola.

In: Investigational New Drugs, Vol. 4, No. 1, 03.1986, p. 39-42.

Research output: Contribution to journalArticle

Lopez, M, Di Lauro, L, Papaldo, P, Lazzaro, B, Ganzina, F & Di Pietro, N 1986, 'Phase II trial with oral idarubicin in advanced breast cancer', Investigational New Drugs, vol. 4, no. 1, pp. 39-42. https://doi.org/10.1007/BF00172014
Lopez M, Di Lauro L, Papaldo P, Lazzaro B, Ganzina F, Di Pietro N. Phase II trial with oral idarubicin in advanced breast cancer. Investigational New Drugs. 1986 Mar;4(1):39-42. https://doi.org/10.1007/BF00172014
Lopez, Massimo ; Di Lauro, Luigi ; Papaldo, Paola ; Lazzaro, Bonaventura ; Ganzina, Fabrizio ; Di Pietro, Nicola. / Phase II trial with oral idarubicin in advanced breast cancer. In: Investigational New Drugs. 1986 ; Vol. 4, No. 1. pp. 39-42.
@article{cbffbd00b2104879a09ac2dccfb87285,
title = "Phase II trial with oral idarubicin in advanced breast cancer",
abstract = "Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50{\%} of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23{\%}. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50{\%} of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 {\%} of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.",
keywords = "breast cancer, chemotherapy, idarubicin",
author = "Massimo Lopez and {Di Lauro}, Luigi and Paola Papaldo and Bonaventura Lazzaro and Fabrizio Ganzina and {Di Pietro}, Nicola",
year = "1986",
month = "3",
doi = "10.1007/BF00172014",
language = "English",
volume = "4",
pages = "39--42",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial with oral idarubicin in advanced breast cancer

AU - Lopez, Massimo

AU - Di Lauro, Luigi

AU - Papaldo, Paola

AU - Lazzaro, Bonaventura

AU - Ganzina, Fabrizio

AU - Di Pietro, Nicola

PY - 1986/3

Y1 - 1986/3

N2 - Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 % of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.

AB - Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81 % of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.

KW - breast cancer

KW - chemotherapy

KW - idarubicin

UR - http://www.scopus.com/inward/record.url?scp=0022578644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022578644&partnerID=8YFLogxK

U2 - 10.1007/BF00172014

DO - 10.1007/BF00172014

M3 - Article

VL - 4

SP - 39

EP - 42

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -